nodes	percent_of_prediction	percent_of_DWPC	metapath
Modafinil—CYP2B6—Thiotepa—urinary bladder cancer	0.19	0.359	CbGbCtD
Modafinil—CYP3A4—Thiotepa—urinary bladder cancer	0.0584	0.11	CbGbCtD
Modafinil—CYP2B6—Cisplatin—urinary bladder cancer	0.0525	0.099	CbGbCtD
Modafinil—ADRA1B—vas deferens—urinary bladder cancer	0.0514	0.562	CbGeAlD
Modafinil—CYP3A5—Etoposide—urinary bladder cancer	0.0406	0.0766	CbGbCtD
Modafinil—CYP1A2—Fluorouracil—urinary bladder cancer	0.0362	0.0683	CbGbCtD
Modafinil—CYP2B6—Doxorubicin—urinary bladder cancer	0.0352	0.0663	CbGbCtD
Modafinil—CYP2C9—Fluorouracil—urinary bladder cancer	0.0326	0.0615	CbGbCtD
Modafinil—CYP1A2—Etoposide—urinary bladder cancer	0.0302	0.057	CbGbCtD
Modafinil—CYP2C9—Cisplatin—urinary bladder cancer	0.0277	0.0523	CbGbCtD
Modafinil—CYP3A4—Etoposide—urinary bladder cancer	0.0158	0.0299	CbGbCtD
Modafinil—CYP3A4—Doxorubicin—urinary bladder cancer	0.0108	0.0204	CbGbCtD
Modafinil—CYP2C19—urine—urinary bladder cancer	0.00728	0.0796	CbGeAlD
Modafinil—CYP1A2—urine—urinary bladder cancer	0.00595	0.065	CbGeAlD
Modafinil—CYP2C9—urine—urinary bladder cancer	0.00564	0.0617	CbGeAlD
Modafinil—CYP3A4—urine—urinary bladder cancer	0.0043	0.047	CbGeAlD
Modafinil—ADRA1B—renal system—urinary bladder cancer	0.00313	0.0342	CbGeAlD
Modafinil—CYP3A5—prostate gland—urinary bladder cancer	0.00206	0.0225	CbGeAlD
Modafinil—Benzphetamine—POR—urinary bladder cancer	0.00157	0.277	CrCbGaD
Modafinil—CYP1A2—renal system—urinary bladder cancer	0.00145	0.0159	CbGeAlD
Modafinil—CYP3A5—renal system—urinary bladder cancer	0.0014	0.0153	CbGeAlD
Modafinil—CYP2B6—renal system—urinary bladder cancer	0.00139	0.0152	CbGeAlD
Modafinil—Carbamazepine—UGT2B7—urinary bladder cancer	0.00135	0.238	CrCbGaD
Modafinil—CYP2C19—vagina—urinary bladder cancer	0.00129	0.0141	CbGeAlD
Modafinil—CYP2B6—female reproductive system—urinary bladder cancer	0.00112	0.0122	CbGeAlD
Modafinil—CYP2C9—female reproductive system—urinary bladder cancer	0.00111	0.0121	CbGeAlD
Modafinil—CYP3A4—renal system—urinary bladder cancer	0.00105	0.0115	CbGeAlD
Modafinil—CYP3A5—vagina—urinary bladder cancer	0.00102	0.0111	CbGeAlD
Modafinil—CYP2B6—vagina—urinary bladder cancer	0.00101	0.011	CbGeAlD
Modafinil—CYP3A4—female reproductive system—urinary bladder cancer	0.000843	0.00922	CbGeAlD
Modafinil—Ketoprofen—CXCL8—urinary bladder cancer	0.000788	0.139	CrCbGaD
Modafinil—Nepafenac—PTGS2—urinary bladder cancer	0.000567	0.0998	CrCbGaD
Modafinil—Oxaprozin—PTGS2—urinary bladder cancer	0.000471	0.0829	CrCbGaD
Modafinil—Fenoprofen—PTGS2—urinary bladder cancer	0.000389	0.0685	CrCbGaD
Modafinil—Phenylbutazone—PTGS2—urinary bladder cancer	0.000312	0.0548	CrCbGaD
Modafinil—Ketoprofen—PTGS2—urinary bladder cancer	0.00023	0.0405	CrCbGaD
Modafinil—Bradycardia—Epirubicin—urinary bladder cancer	0.000203	0.000728	CcSEcCtD
Modafinil—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000202	0.000727	CcSEcCtD
Modafinil—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000201	0.000723	CcSEcCtD
Modafinil—Urticaria—Etoposide—urinary bladder cancer	0.0002	0.00072	CcSEcCtD
Modafinil—Stomatitis—Doxorubicin—urinary bladder cancer	0.0002	0.000719	CcSEcCtD
Modafinil—Rhinitis—Epirubicin—urinary bladder cancer	0.000199	0.000717	CcSEcCtD
Modafinil—Body temperature increased—Etoposide—urinary bladder cancer	0.000199	0.000717	CcSEcCtD
Modafinil—Abdominal pain—Etoposide—urinary bladder cancer	0.000199	0.000717	CcSEcCtD
Modafinil—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000199	0.000717	CcSEcCtD
Modafinil—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000199	0.000717	CcSEcCtD
Modafinil—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000199	0.000714	CcSEcCtD
Modafinil—Asthenia—Cisplatin—urinary bladder cancer	0.000197	0.00071	CcSEcCtD
Modafinil—Pharyngitis—Epirubicin—urinary bladder cancer	0.000197	0.00071	CcSEcCtD
Modafinil—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000197	0.00071	CcSEcCtD
Modafinil—Sweating—Doxorubicin—urinary bladder cancer	0.000197	0.000707	CcSEcCtD
Modafinil—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000196	0.000707	CcSEcCtD
Modafinil—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000196	0.000705	CcSEcCtD
Modafinil—Haematuria—Doxorubicin—urinary bladder cancer	0.000195	0.000703	CcSEcCtD
Modafinil—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000195	0.000703	CcSEcCtD
Modafinil—Urethral disorder—Epirubicin—urinary bladder cancer	0.000195	0.000701	CcSEcCtD
Modafinil—Epistaxis—Doxorubicin—urinary bladder cancer	0.000193	0.000696	CcSEcCtD
Modafinil—Angiopathy—Methotrexate—urinary bladder cancer	0.000193	0.000694	CcSEcCtD
Modafinil—Sinusitis—Doxorubicin—urinary bladder cancer	0.000192	0.000692	CcSEcCtD
Modafinil—Immune system disorder—Methotrexate—urinary bladder cancer	0.000192	0.000691	CcSEcCtD
Modafinil—Dizziness—Fluorouracil—urinary bladder cancer	0.000192	0.00069	CcSEcCtD
Modafinil—Visual impairment—Epirubicin—urinary bladder cancer	0.000192	0.000689	CcSEcCtD
Modafinil—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000192	0.000689	CcSEcCtD
Modafinil—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000191	0.000688	CcSEcCtD
Modafinil—Chills—Methotrexate—urinary bladder cancer	0.000191	0.000686	CcSEcCtD
Modafinil—Diarrhoea—Cisplatin—urinary bladder cancer	0.000188	0.000677	CcSEcCtD
Modafinil—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000188	0.000676	CcSEcCtD
Modafinil—Vomiting—Gemcitabine—urinary bladder cancer	0.000188	0.000675	CcSEcCtD
Modafinil—Bradycardia—Doxorubicin—urinary bladder cancer	0.000187	0.000674	CcSEcCtD
Modafinil—Mental disorder—Methotrexate—urinary bladder cancer	0.000186	0.00067	CcSEcCtD
Modafinil—Rash—Gemcitabine—urinary bladder cancer	0.000186	0.00067	CcSEcCtD
Modafinil—Dermatitis—Gemcitabine—urinary bladder cancer	0.000186	0.000669	CcSEcCtD
Modafinil—Hypersensitivity—Etoposide—urinary bladder cancer	0.000186	0.000668	CcSEcCtD
Modafinil—Malnutrition—Methotrexate—urinary bladder cancer	0.000185	0.000666	CcSEcCtD
Modafinil—Headache—Gemcitabine—urinary bladder cancer	0.000185	0.000665	CcSEcCtD
Modafinil—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000185	0.000664	CcSEcCtD
Modafinil—Vomiting—Fluorouracil—urinary bladder cancer	0.000185	0.000664	CcSEcCtD
Modafinil—Rhinitis—Doxorubicin—urinary bladder cancer	0.000185	0.000664	CcSEcCtD
Modafinil—Rash—Fluorouracil—urinary bladder cancer	0.000183	0.000658	CcSEcCtD
Modafinil—Dermatitis—Fluorouracil—urinary bladder cancer	0.000183	0.000658	CcSEcCtD
Modafinil—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000183	0.000657	CcSEcCtD
Modafinil—Headache—Fluorouracil—urinary bladder cancer	0.000182	0.000654	CcSEcCtD
Modafinil—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000182	0.000654	CcSEcCtD
Modafinil—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000181	0.000652	CcSEcCtD
Modafinil—Dysgeusia—Methotrexate—urinary bladder cancer	0.000181	0.000652	CcSEcCtD
Modafinil—Asthenia—Etoposide—urinary bladder cancer	0.000181	0.000651	CcSEcCtD
Modafinil—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000181	0.000651	CcSEcCtD
Modafinil—Angiopathy—Epirubicin—urinary bladder cancer	0.00018	0.000649	CcSEcCtD
Modafinil—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00018	0.000649	CcSEcCtD
Modafinil—Immune system disorder—Epirubicin—urinary bladder cancer	0.00018	0.000646	CcSEcCtD
Modafinil—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000179	0.000645	CcSEcCtD
Modafinil—Back pain—Methotrexate—urinary bladder cancer	0.000179	0.000644	CcSEcCtD
Modafinil—Chills—Epirubicin—urinary bladder cancer	0.000178	0.000642	CcSEcCtD
Modafinil—Pruritus—Etoposide—urinary bladder cancer	0.000178	0.000642	CcSEcCtD
Modafinil—Arrhythmia—Epirubicin—urinary bladder cancer	0.000178	0.000639	CcSEcCtD
Modafinil—Visual impairment—Doxorubicin—urinary bladder cancer	0.000177	0.000638	CcSEcCtD
Modafinil—Nausea—Gemcitabine—urinary bladder cancer	0.000175	0.000631	CcSEcCtD
Modafinil—Vomiting—Cisplatin—urinary bladder cancer	0.000175	0.000629	CcSEcCtD
Modafinil—Mental disorder—Epirubicin—urinary bladder cancer	0.000174	0.000627	CcSEcCtD
Modafinil—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000174	0.000626	CcSEcCtD
Modafinil—Rash—Cisplatin—urinary bladder cancer	0.000174	0.000624	CcSEcCtD
Modafinil—Dermatitis—Cisplatin—urinary bladder cancer	0.000173	0.000624	CcSEcCtD
Modafinil—Malnutrition—Epirubicin—urinary bladder cancer	0.000173	0.000623	CcSEcCtD
Modafinil—Diarrhoea—Etoposide—urinary bladder cancer	0.000172	0.00062	CcSEcCtD
Modafinil—Nausea—Fluorouracil—urinary bladder cancer	0.000172	0.00062	CcSEcCtD
Modafinil—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000172	0.000617	CcSEcCtD
Modafinil—Anaemia—Methotrexate—urinary bladder cancer	0.000171	0.000615	CcSEcCtD
Modafinil—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000171	0.000614	CcSEcCtD
Modafinil—Flatulence—Epirubicin—urinary bladder cancer	0.000171	0.000614	CcSEcCtD
Modafinil—Tension—Epirubicin—urinary bladder cancer	0.00017	0.000611	CcSEcCtD
Modafinil—Dysgeusia—Epirubicin—urinary bladder cancer	0.00017	0.00061	CcSEcCtD
Modafinil—Nervousness—Epirubicin—urinary bladder cancer	0.000168	0.000605	CcSEcCtD
Modafinil—Back pain—Epirubicin—urinary bladder cancer	0.000167	0.000602	CcSEcCtD
Modafinil—Angiopathy—Doxorubicin—urinary bladder cancer	0.000167	0.000601	CcSEcCtD
Modafinil—Malaise—Methotrexate—urinary bladder cancer	0.000167	0.0006	CcSEcCtD
Modafinil—Dizziness—Etoposide—urinary bladder cancer	0.000167	0.0006	CcSEcCtD
Modafinil—Muscle spasms—Epirubicin—urinary bladder cancer	0.000166	0.000599	CcSEcCtD
Modafinil—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000166	0.000598	CcSEcCtD
Modafinil—Vertigo—Methotrexate—urinary bladder cancer	0.000166	0.000598	CcSEcCtD
Modafinil—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000166	0.000597	CcSEcCtD
Modafinil—Chills—Doxorubicin—urinary bladder cancer	0.000165	0.000594	CcSEcCtD
Modafinil—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000164	0.000591	CcSEcCtD
Modafinil—Nausea—Cisplatin—urinary bladder cancer	0.000163	0.000588	CcSEcCtD
Modafinil—Cough—Methotrexate—urinary bladder cancer	0.000161	0.000581	CcSEcCtD
Modafinil—Mental disorder—Doxorubicin—urinary bladder cancer	0.000161	0.00058	CcSEcCtD
Modafinil—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000161	0.000578	CcSEcCtD
Modafinil—Convulsion—Methotrexate—urinary bladder cancer	0.00016	0.000577	CcSEcCtD
Modafinil—Vomiting—Etoposide—urinary bladder cancer	0.00016	0.000577	CcSEcCtD
Modafinil—Malnutrition—Doxorubicin—urinary bladder cancer	0.00016	0.000576	CcSEcCtD
Modafinil—Anaemia—Epirubicin—urinary bladder cancer	0.00016	0.000576	CcSEcCtD
Modafinil—Agitation—Epirubicin—urinary bladder cancer	0.000159	0.000572	CcSEcCtD
Modafinil—Rash—Etoposide—urinary bladder cancer	0.000159	0.000572	CcSEcCtD
Modafinil—Dermatitis—Etoposide—urinary bladder cancer	0.000159	0.000571	CcSEcCtD
Modafinil—Headache—Etoposide—urinary bladder cancer	0.000158	0.000568	CcSEcCtD
Modafinil—Flatulence—Doxorubicin—urinary bladder cancer	0.000158	0.000568	CcSEcCtD
Modafinil—Chest pain—Methotrexate—urinary bladder cancer	0.000158	0.000567	CcSEcCtD
Modafinil—Myalgia—Methotrexate—urinary bladder cancer	0.000158	0.000567	CcSEcCtD
Modafinil—Arthralgia—Methotrexate—urinary bladder cancer	0.000158	0.000567	CcSEcCtD
Modafinil—Tension—Doxorubicin—urinary bladder cancer	0.000157	0.000566	CcSEcCtD
Modafinil—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000157	0.000564	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000156	0.000563	CcSEcCtD
Modafinil—Malaise—Epirubicin—urinary bladder cancer	0.000156	0.000562	CcSEcCtD
Modafinil—Discomfort—Methotrexate—urinary bladder cancer	0.000156	0.00056	CcSEcCtD
Modafinil—Nervousness—Doxorubicin—urinary bladder cancer	0.000156	0.00056	CcSEcCtD
Modafinil—Vertigo—Epirubicin—urinary bladder cancer	0.000156	0.00056	CcSEcCtD
Modafinil—Syncope—Epirubicin—urinary bladder cancer	0.000155	0.000559	CcSEcCtD
Modafinil—Back pain—Doxorubicin—urinary bladder cancer	0.000155	0.000557	CcSEcCtD
Modafinil—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000154	0.000554	CcSEcCtD
Modafinil—Palpitations—Epirubicin—urinary bladder cancer	0.000153	0.00055	CcSEcCtD
Modafinil—Confusional state—Methotrexate—urinary bladder cancer	0.000152	0.000548	CcSEcCtD
Modafinil—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000152	0.000547	CcSEcCtD
Modafinil—Cough—Epirubicin—urinary bladder cancer	0.000151	0.000543	CcSEcCtD
Modafinil—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000151	0.000543	CcSEcCtD
Modafinil—Convulsion—Epirubicin—urinary bladder cancer	0.00015	0.00054	CcSEcCtD
Modafinil—Infection—Methotrexate—urinary bladder cancer	0.00015	0.00054	CcSEcCtD
Modafinil—Nausea—Etoposide—urinary bladder cancer	0.00015	0.000539	CcSEcCtD
Modafinil—Hypertension—Epirubicin—urinary bladder cancer	0.00015	0.000538	CcSEcCtD
Modafinil—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000149	0.000535	CcSEcCtD
Modafinil—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000148	0.000533	CcSEcCtD
Modafinil—Anaemia—Doxorubicin—urinary bladder cancer	0.000148	0.000533	CcSEcCtD
Modafinil—Arthralgia—Epirubicin—urinary bladder cancer	0.000147	0.00053	CcSEcCtD
Modafinil—Chest pain—Epirubicin—urinary bladder cancer	0.000147	0.00053	CcSEcCtD
Modafinil—Myalgia—Epirubicin—urinary bladder cancer	0.000147	0.00053	CcSEcCtD
Modafinil—Agitation—Doxorubicin—urinary bladder cancer	0.000147	0.00053	CcSEcCtD
Modafinil—Anxiety—Epirubicin—urinary bladder cancer	0.000147	0.000528	CcSEcCtD
Modafinil—Skin disorder—Methotrexate—urinary bladder cancer	0.000147	0.000528	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000146	0.000527	CcSEcCtD
Modafinil—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000146	0.000525	CcSEcCtD
Modafinil—Discomfort—Epirubicin—urinary bladder cancer	0.000146	0.000524	CcSEcCtD
Modafinil—Malaise—Doxorubicin—urinary bladder cancer	0.000144	0.00052	CcSEcCtD
Modafinil—Dry mouth—Epirubicin—urinary bladder cancer	0.000144	0.000519	CcSEcCtD
Modafinil—Vertigo—Doxorubicin—urinary bladder cancer	0.000144	0.000518	CcSEcCtD
Modafinil—Anorexia—Methotrexate—urinary bladder cancer	0.000144	0.000518	CcSEcCtD
Modafinil—Syncope—Doxorubicin—urinary bladder cancer	0.000144	0.000517	CcSEcCtD
Modafinil—Confusional state—Epirubicin—urinary bladder cancer	0.000142	0.000513	CcSEcCtD
Modafinil—Palpitations—Doxorubicin—urinary bladder cancer	0.000142	0.000509	CcSEcCtD
Modafinil—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000141	0.000508	CcSEcCtD
Modafinil—Oedema—Epirubicin—urinary bladder cancer	0.000141	0.000508	CcSEcCtD
Modafinil—Hypotension—Methotrexate—urinary bladder cancer	0.000141	0.000508	CcSEcCtD
Modafinil—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000141	0.000507	CcSEcCtD
Modafinil—Infection—Epirubicin—urinary bladder cancer	0.00014	0.000505	CcSEcCtD
Modafinil—Cough—Doxorubicin—urinary bladder cancer	0.00014	0.000503	CcSEcCtD
Modafinil—Shock—Epirubicin—urinary bladder cancer	0.000139	0.0005	CcSEcCtD
Modafinil—Convulsion—Doxorubicin—urinary bladder cancer	0.000139	0.000499	CcSEcCtD
Modafinil—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000139	0.000498	CcSEcCtD
Modafinil—Hypertension—Doxorubicin—urinary bladder cancer	0.000138	0.000498	CcSEcCtD
Modafinil—Tachycardia—Epirubicin—urinary bladder cancer	0.000138	0.000496	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000138	0.000495	CcSEcCtD
Modafinil—Skin disorder—Epirubicin—urinary bladder cancer	0.000137	0.000494	CcSEcCtD
Modafinil—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000137	0.000491	CcSEcCtD
Modafinil—Insomnia—Methotrexate—urinary bladder cancer	0.000137	0.000491	CcSEcCtD
Modafinil—Myalgia—Doxorubicin—urinary bladder cancer	0.000136	0.000491	CcSEcCtD
Modafinil—Arthralgia—Doxorubicin—urinary bladder cancer	0.000136	0.000491	CcSEcCtD
Modafinil—Chest pain—Doxorubicin—urinary bladder cancer	0.000136	0.000491	CcSEcCtD
Modafinil—Anxiety—Doxorubicin—urinary bladder cancer	0.000136	0.000489	CcSEcCtD
Modafinil—Paraesthesia—Methotrexate—urinary bladder cancer	0.000136	0.000488	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000135	0.000487	CcSEcCtD
Modafinil—Discomfort—Doxorubicin—urinary bladder cancer	0.000135	0.000485	CcSEcCtD
Modafinil—Anorexia—Epirubicin—urinary bladder cancer	0.000135	0.000485	CcSEcCtD
Modafinil—Dyspnoea—Methotrexate—urinary bladder cancer	0.000135	0.000484	CcSEcCtD
Modafinil—Somnolence—Methotrexate—urinary bladder cancer	0.000134	0.000483	CcSEcCtD
Modafinil—Dry mouth—Doxorubicin—urinary bladder cancer	0.000133	0.00048	CcSEcCtD
Modafinil—Dyspepsia—Methotrexate—urinary bladder cancer	0.000133	0.000478	CcSEcCtD
Modafinil—Hypotension—Epirubicin—urinary bladder cancer	0.000132	0.000475	CcSEcCtD
Modafinil—Confusional state—Doxorubicin—urinary bladder cancer	0.000132	0.000474	CcSEcCtD
Modafinil—Decreased appetite—Methotrexate—urinary bladder cancer	0.000131	0.000472	CcSEcCtD
Modafinil—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000131	0.00047	CcSEcCtD
Modafinil—Oedema—Doxorubicin—urinary bladder cancer	0.000131	0.00047	CcSEcCtD
Modafinil—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00013	0.000469	CcSEcCtD
Modafinil—Fatigue—Methotrexate—urinary bladder cancer	0.00013	0.000468	CcSEcCtD
Modafinil—Infection—Doxorubicin—urinary bladder cancer	0.00013	0.000467	CcSEcCtD
Modafinil—Pain—Methotrexate—urinary bladder cancer	0.000129	0.000464	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000129	0.000463	CcSEcCtD
Modafinil—Shock—Doxorubicin—urinary bladder cancer	0.000129	0.000463	CcSEcCtD
Modafinil—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000128	0.000461	CcSEcCtD
Modafinil—Insomnia—Epirubicin—urinary bladder cancer	0.000128	0.00046	CcSEcCtD
Modafinil—Tachycardia—Doxorubicin—urinary bladder cancer	0.000128	0.000459	CcSEcCtD
Modafinil—Skin disorder—Doxorubicin—urinary bladder cancer	0.000127	0.000457	CcSEcCtD
Modafinil—Paraesthesia—Epirubicin—urinary bladder cancer	0.000127	0.000456	CcSEcCtD
Modafinil—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000126	0.000455	CcSEcCtD
Modafinil—Dyspnoea—Epirubicin—urinary bladder cancer	0.000126	0.000453	CcSEcCtD
Modafinil—Somnolence—Epirubicin—urinary bladder cancer	0.000126	0.000452	CcSEcCtD
Modafinil—Anorexia—Doxorubicin—urinary bladder cancer	0.000125	0.000448	CcSEcCtD
Modafinil—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000124	0.000448	CcSEcCtD
Modafinil—Dyspepsia—Epirubicin—urinary bladder cancer	0.000124	0.000447	CcSEcCtD
Modafinil—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000123	0.000444	CcSEcCtD
Modafinil—Decreased appetite—Epirubicin—urinary bladder cancer	0.000123	0.000442	CcSEcCtD
Modafinil—Hypotension—Doxorubicin—urinary bladder cancer	0.000122	0.000439	CcSEcCtD
Modafinil—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000122	0.000439	CcSEcCtD
Modafinil—Fatigue—Epirubicin—urinary bladder cancer	0.000122	0.000438	CcSEcCtD
Modafinil—Pain—Epirubicin—urinary bladder cancer	0.000121	0.000435	CcSEcCtD
Modafinil—Constipation—Epirubicin—urinary bladder cancer	0.000121	0.000435	CcSEcCtD
Modafinil—Urticaria—Methotrexate—urinary bladder cancer	0.00012	0.000431	CcSEcCtD
Modafinil—Abdominal pain—Methotrexate—urinary bladder cancer	0.000119	0.000429	CcSEcCtD
Modafinil—Body temperature increased—Methotrexate—urinary bladder cancer	0.000119	0.000429	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000119	0.000428	CcSEcCtD
Modafinil—Insomnia—Doxorubicin—urinary bladder cancer	0.000118	0.000425	CcSEcCtD
Modafinil—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000117	0.000422	CcSEcCtD
Modafinil—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000117	0.000419	CcSEcCtD
Modafinil—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000116	0.000419	CcSEcCtD
Modafinil—Somnolence—Doxorubicin—urinary bladder cancer	0.000116	0.000418	CcSEcCtD
Modafinil—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000116	0.000416	CcSEcCtD
Modafinil—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000115	0.000414	CcSEcCtD
Modafinil—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000114	0.000409	CcSEcCtD
Modafinil—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000113	0.000406	CcSEcCtD
Modafinil—Fatigue—Doxorubicin—urinary bladder cancer	0.000113	0.000405	CcSEcCtD
Modafinil—Urticaria—Epirubicin—urinary bladder cancer	0.000112	0.000404	CcSEcCtD
Modafinil—Constipation—Doxorubicin—urinary bladder cancer	0.000112	0.000402	CcSEcCtD
Modafinil—Pain—Doxorubicin—urinary bladder cancer	0.000112	0.000402	CcSEcCtD
Modafinil—Body temperature increased—Epirubicin—urinary bladder cancer	0.000112	0.000402	CcSEcCtD
Modafinil—Abdominal pain—Epirubicin—urinary bladder cancer	0.000112	0.000402	CcSEcCtD
Modafinil—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000111	0.0004	CcSEcCtD
Modafinil—Asthenia—Methotrexate—urinary bladder cancer	0.000108	0.00039	CcSEcCtD
Modafinil—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000108	0.000388	CcSEcCtD
Modafinil—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000107	0.000385	CcSEcCtD
Modafinil—Pruritus—Methotrexate—urinary bladder cancer	0.000107	0.000384	CcSEcCtD
Modafinil—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000104	0.000374	CcSEcCtD
Modafinil—Urticaria—Doxorubicin—urinary bladder cancer	0.000104	0.000374	CcSEcCtD
Modafinil—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000103	0.000372	CcSEcCtD
Modafinil—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000103	0.000372	CcSEcCtD
Modafinil—Diarrhoea—Methotrexate—urinary bladder cancer	0.000103	0.000372	CcSEcCtD
Modafinil—Asthenia—Epirubicin—urinary bladder cancer	0.000101	0.000365	CcSEcCtD
Modafinil—Pruritus—Epirubicin—urinary bladder cancer	0.0001	0.00036	CcSEcCtD
Modafinil—Dizziness—Methotrexate—urinary bladder cancer	9.99e-05	0.000359	CcSEcCtD
Modafinil—Diarrhoea—Epirubicin—urinary bladder cancer	9.67e-05	0.000348	CcSEcCtD
Modafinil—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.63e-05	0.000347	CcSEcCtD
Modafinil—Vomiting—Methotrexate—urinary bladder cancer	9.6e-05	0.000345	CcSEcCtD
Modafinil—Rash—Methotrexate—urinary bladder cancer	9.52e-05	0.000342	CcSEcCtD
Modafinil—Dermatitis—Methotrexate—urinary bladder cancer	9.51e-05	0.000342	CcSEcCtD
Modafinil—Headache—Methotrexate—urinary bladder cancer	9.46e-05	0.00034	CcSEcCtD
Modafinil—Asthenia—Doxorubicin—urinary bladder cancer	9.38e-05	0.000337	CcSEcCtD
Modafinil—Dizziness—Epirubicin—urinary bladder cancer	9.35e-05	0.000336	CcSEcCtD
Modafinil—Pruritus—Doxorubicin—urinary bladder cancer	9.25e-05	0.000333	CcSEcCtD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	9.03e-05	0.000957	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	9.03e-05	0.000957	CbGpPWpGaD
Modafinil—Vomiting—Epirubicin—urinary bladder cancer	8.99e-05	0.000323	CcSEcCtD
Modafinil—Nausea—Methotrexate—urinary bladder cancer	8.97e-05	0.000323	CcSEcCtD
Modafinil—Diarrhoea—Doxorubicin—urinary bladder cancer	8.95e-05	0.000322	CcSEcCtD
Modafinil—Rash—Epirubicin—urinary bladder cancer	8.91e-05	0.00032	CcSEcCtD
Modafinil—Dermatitis—Epirubicin—urinary bladder cancer	8.9e-05	0.00032	CcSEcCtD
Modafinil—Headache—Epirubicin—urinary bladder cancer	8.85e-05	0.000318	CcSEcCtD
Modafinil—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	8.85e-05	0.000938	CbGpPWpGaD
Modafinil—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	8.78e-05	0.000931	CbGpPWpGaD
Modafinil—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.73e-05	0.000925	CbGpPWpGaD
Modafinil—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.66e-05	0.000918	CbGpPWpGaD
Modafinil—Dizziness—Doxorubicin—urinary bladder cancer	8.65e-05	0.000311	CcSEcCtD
Modafinil—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	8.61e-05	0.000913	CbGpPWpGaD
Modafinil—Nausea—Epirubicin—urinary bladder cancer	8.39e-05	0.000302	CcSEcCtD
Modafinil—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	8.35e-05	0.000886	CbGpPWpGaD
Modafinil—Vomiting—Doxorubicin—urinary bladder cancer	8.31e-05	0.000299	CcSEcCtD
Modafinil—Rash—Doxorubicin—urinary bladder cancer	8.24e-05	0.000297	CcSEcCtD
Modafinil—Dermatitis—Doxorubicin—urinary bladder cancer	8.24e-05	0.000296	CcSEcCtD
Modafinil—Headache—Doxorubicin—urinary bladder cancer	8.19e-05	0.000295	CcSEcCtD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	8.09e-05	0.000858	CbGpPWpGaD
Modafinil—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	8.07e-05	0.000856	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	8.06e-05	0.000854	CbGpPWpGaD
Modafinil—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.96e-05	0.000844	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	7.91e-05	0.000839	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	7.91e-05	0.000839	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—GSTZ1—urinary bladder cancer	7.81e-05	0.000828	CbGpPWpGaD
Modafinil—Nausea—Doxorubicin—urinary bladder cancer	7.77e-05	0.000279	CcSEcCtD
Modafinil—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	7.63e-05	0.000809	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	7.54e-05	0.000799	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	7.54e-05	0.000799	CbGpPWpGaD
Modafinil—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	7.5e-05	0.000796	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	7.48e-05	0.000793	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—GSTO2—urinary bladder cancer	7.4e-05	0.000785	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—NAT1—urinary bladder cancer	7.4e-05	0.000785	CbGpPWpGaD
Modafinil—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.4e-05	0.000785	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	7.23e-05	0.000767	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—NAT1—urinary bladder cancer	7.23e-05	0.000767	CbGpPWpGaD
Modafinil—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	6.9e-05	0.000731	CbGpPWpGaD
Modafinil—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.8e-05	0.000721	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—UGT2B7—urinary bladder cancer	6.77e-05	0.000718	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	6.62e-05	0.000701	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	6.36e-05	0.000674	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—CYP4B1—urinary bladder cancer	6.09e-05	0.000646	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	5.96e-05	0.000632	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	5.9e-05	0.000625	CbGpPWpGaD
Modafinil—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	5.79e-05	0.000614	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—HDAC4—urinary bladder cancer	5.78e-05	0.000613	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—SLC19A1—urinary bladder cancer	5.76e-05	0.00061	CbGpPWpGaD
Modafinil—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.71e-05	0.000606	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	5.63e-05	0.000596	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PRSS3—urinary bladder cancer	5.61e-05	0.000595	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	5.59e-05	0.000593	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—NAT1—urinary bladder cancer	5.59e-05	0.000593	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.5e-05	0.000583	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	5.48e-05	0.000581	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	5.38e-05	0.00057	CbGpPWpGaD
Modafinil—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	5.32e-05	0.000564	CbGpPWpGaD
Modafinil—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.25e-05	0.000556	CbGpPWpGaD
Modafinil—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	5.13e-05	0.000543	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	5.11e-05	0.000542	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	5.1e-05	0.000541	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—NAT1—urinary bladder cancer	5.1e-05	0.000541	CbGpPWpGaD
Modafinil—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	5.06e-05	0.000536	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.02e-05	0.000532	CbGpPWpGaD
Modafinil—SLC6A3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	4.94e-05	0.000524	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—GLI1—urinary bladder cancer	4.85e-05	0.000514	CbGpPWpGaD
Modafinil—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	4.78e-05	0.000507	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	4.66e-05	0.000494	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	4.61e-05	0.000488	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	4.6e-05	0.000487	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—TYMP—urinary bladder cancer	4.48e-05	0.000475	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—TYMP—urinary bladder cancer	4.38e-05	0.000465	CbGpPWpGaD
Modafinil—SLC6A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.37e-05	0.000463	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NAT1—urinary bladder cancer	4.36e-05	0.000462	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	4.36e-05	0.000462	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	4.35e-05	0.000461	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.29e-05	0.000454	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	4.24e-05	0.000449	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	4.2e-05	0.000445	CbGpPWpGaD
Modafinil—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	4.06e-05	0.000431	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—NAT2—urinary bladder cancer	4.05e-05	0.00043	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	3.99e-05	0.000423	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	3.97e-05	0.00042	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—NAT2—urinary bladder cancer	3.96e-05	0.00042	CbGpPWpGaD
Modafinil—ADRA1B—GPCR ligand binding—CXCL8—urinary bladder cancer	3.9e-05	0.000414	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	3.86e-05	0.00041	CbGpPWpGaD
Modafinil—SLC6A3—Neuronal System—HRAS—urinary bladder cancer	3.79e-05	0.000401	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	3.59e-05	0.00038	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.55e-05	0.000376	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—RRM2—urinary bladder cancer	3.5e-05	0.000371	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—RRM2—urinary bladder cancer	3.42e-05	0.000363	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.4e-05	0.00036	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	3.39e-05	0.000359	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—TYMP—urinary bladder cancer	3.39e-05	0.000359	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.36e-05	0.000357	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.36e-05	0.000357	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—RBX1—urinary bladder cancer	3.32e-05	0.000352	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	3.3e-05	0.00035	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.25e-05	0.000345	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—ENO2—urinary bladder cancer	3.24e-05	0.000344	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	3.24e-05	0.000344	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	3.17e-05	0.000336	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—ENO2—urinary bladder cancer	3.17e-05	0.000336	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	3.14e-05	0.000333	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TSC1—urinary bladder cancer	3.12e-05	0.000331	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.1e-05	0.000329	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.09e-05	0.000328	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.08e-05	0.000326	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	3.07e-05	0.000326	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—NAT2—urinary bladder cancer	3.06e-05	0.000325	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—JAG1—urinary bladder cancer	2.97e-05	0.000315	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.97e-05	0.000315	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.79e-05	0.000296	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.77e-05	0.000294	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.65e-05	0.000281	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—RRM2—urinary bladder cancer	2.64e-05	0.00028	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—TYMP—urinary bladder cancer	2.64e-05	0.00028	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.62e-05	0.000277	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—NQO1—urinary bladder cancer	2.61e-05	0.000277	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—NQO1—urinary bladder cancer	2.55e-05	0.000271	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.55e-05	0.00027	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.54e-05	0.000269	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—RHOA—urinary bladder cancer	2.51e-05	0.000266	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.45e-05	0.00026	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.45e-05	0.00026	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.44e-05	0.000258	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.41e-05	0.000256	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—S100B—urinary bladder cancer	2.41e-05	0.000255	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NAT2—urinary bladder cancer	2.39e-05	0.000253	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	2.38e-05	0.000252	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.34e-05	0.000248	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—RHOA—urinary bladder cancer	2.28e-05	0.000242	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.23e-05	0.000237	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.23e-05	0.000237	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.22e-05	0.000235	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.21e-05	0.000234	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	2.18e-05	0.000231	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.17e-05	0.00023	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—NCOR1—urinary bladder cancer	2.16e-05	0.000229	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.13e-05	0.000226	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	2.13e-05	0.000226	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—IL2—urinary bladder cancer	2.11e-05	0.000224	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—RRM2—urinary bladder cancer	2.06e-05	0.000219	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.04e-05	0.000216	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—TYMS—urinary bladder cancer	2.03e-05	0.000215	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—CXCL8—urinary bladder cancer	2e-05	0.000212	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	2e-05	0.000212	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	2e-05	0.000212	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.98e-05	0.00021	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.97e-05	0.000209	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.96e-05	0.000208	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.96e-05	0.000208	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—GPX1—urinary bladder cancer	1.92e-05	0.000203	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.92e-05	0.000203	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—IL2—urinary bladder cancer	1.91e-05	0.000203	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.91e-05	0.000202	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.91e-05	0.000202	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TERT—urinary bladder cancer	1.91e-05	0.000202	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.9e-05	0.000201	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	1.88e-05	0.0002	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.87e-05	0.000199	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.85e-05	0.000196	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.84e-05	0.000195	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.84e-05	0.000195	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.82e-05	0.000193	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.8e-05	0.000191	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.77e-05	0.000188	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—FGFR3—urinary bladder cancer	1.75e-05	0.000186	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.75e-05	0.000185	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.73e-05	0.000183	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—ESR1—urinary bladder cancer	1.7e-05	0.00018	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.67e-05	0.000177	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.65e-05	0.000175	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.59e-05	0.000169	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.59e-05	0.000169	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.54e-05	0.000163	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.53e-05	0.000162	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.52e-05	0.000162	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.51e-05	0.00016	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.51e-05	0.00016	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.5e-05	0.000159	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.49e-05	0.000158	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CREBBP—urinary bladder cancer	1.49e-05	0.000158	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.47e-05	0.000156	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.47e-05	0.000156	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—IGF1—urinary bladder cancer	1.47e-05	0.000156	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—EGFR—urinary bladder cancer	1.46e-05	0.000155	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.45e-05	0.000154	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.45e-05	0.000154	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.44e-05	0.000152	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.43e-05	0.000151	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.42e-05	0.000151	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.4e-05	0.000149	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.4e-05	0.000148	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	1.38e-05	0.000147	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.38e-05	0.000146	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.38e-05	0.000146	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.38e-05	0.000146	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	1.35e-05	0.000143	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.35e-05	0.000143	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.34e-05	0.000142	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.32e-05	0.00014	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.3e-05	0.000138	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.3e-05	0.000138	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.28e-05	0.000136	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	1.25e-05	0.000132	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.24e-05	0.000132	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.22e-05	0.000129	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.19e-05	0.000126	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.19e-05	0.000126	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	1.18e-05	0.000125	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.18e-05	0.000125	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.18e-05	0.000125	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	1.18e-05	0.000125	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	1.13e-05	0.00012	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.13e-05	0.00012	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	1.13e-05	0.00012	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.11e-05	0.000118	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.1e-05	0.000117	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	1.1e-05	0.000117	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.08e-05	0.000115	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	1.07e-05	0.000113	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.07e-05	0.000113	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	1.06e-05	0.000113	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.04e-05	0.00011	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.04e-05	0.00011	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	1.01e-05	0.000108	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.9e-06	0.000105	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PPARG—urinary bladder cancer	9.89e-06	0.000105	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	9.87e-06	0.000105	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PTEN—urinary bladder cancer	9.85e-06	0.000104	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PTEN—urinary bladder cancer	9.62e-06	0.000102	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	9.5e-06	0.000101	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—EP300—urinary bladder cancer	9.39e-06	9.96e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—TYMS—urinary bladder cancer	9.21e-06	9.76e-05	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—EP300—urinary bladder cancer	9.18e-06	9.73e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	9.1e-06	9.65e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	9.1e-06	9.65e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	8.84e-06	9.38e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8.71e-06	9.24e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	8.65e-06	9.17e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	8.56e-06	9.07e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	8.53e-06	9.05e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PPARG—urinary bladder cancer	8.45e-06	8.96e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	8.17e-06	8.66e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	8.12e-06	8.61e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	8.04e-06	8.53e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	7.78e-06	8.25e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PTEN—urinary bladder cancer	7.44e-06	7.89e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	7.26e-06	7.7e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—EP300—urinary bladder cancer	7.1e-06	7.52e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	6.94e-06	7.36e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PTEN—urinary bladder cancer	6.78e-06	7.19e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	6.65e-06	7.05e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6.52e-06	6.91e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—EP300—urinary bladder cancer	6.47e-06	6.86e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.27e-06	6.64e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PTEN—urinary bladder cancer	5.8e-06	6.15e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—EP300—urinary bladder cancer	5.53e-06	5.86e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.13e-06	5.44e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.47e-06	4.74e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.27e-06	4.52e-05	CbGpPWpGaD
